Effect of Icariin on UDP-Glucuronosyltransferases in Mouse Liver

Abstract

Icariin is a flavonol glycoside isolated from Epimedium genus and has been used in the treatment of sexual dysfunction and osteoporosis. Our laboratory has shown that icariin is beneficial in brain disorders and cardiovascular diseases. Since icariin is widely used with other herbs and drugs, to understand its potential herb-drug interactions is of importance. Recently, icariin was shown to inhibit UDP-glucuronosyltransferases, particularly the Ugt1 family enzymes in vitro, but little is known about such effects in vivo. This study investigated the effects of icariin on the expression of UDP-glucuronosyltransferases and cytochrome P450 enzymes in the livers of mice. Adult mice were treated with icariin at doses of 0, 40, 80, 160, and 320 mg/kg, p. o., for 7 days. Phenobarbital (120 mg/kg, p. o.) and rifampin (360 mg/kg, p. o.) were given twice daily for 3 days as positive controls. The livers were removed to determine UDP-glucuronosyltransferase activity and total RNA isolation. The UDP-glucuronosyltransferase activities towards 2-aminophenol were basically unaltered by the treatments. The expression of Cyp2b10 was increased 35-fold by phenobarbital, and Cyp3a11 was increased 4.5-fold by rifampin. Icariin did not affect Cyp2b10 and Cyp3a11 expression, but unexpectedly increased Cyp4a14 expression. Both phenobarbital and rifampin increased Ugt1a1, Ugt1a6, Ugt1a9, and icariin but did not show any suppressive effects on the Ugt1 family genes. Icariin at the highest dose (320 mg/kg) slightly increased Ugt2b1, Ugt2b5, and Ugt2b36. These findings indicate that icariin did not suppress UDP-glucuronosyltransferase expression, instead, it increased the mRNA of Cyp4a14 and slightly increased Ugt2b isoforms in mouse livers.

Key words

icariiin - phenobarbital - rifampin - cytochrome P450 - UDP-glucuronosyltransferase

• References

• 1 de Lima Toccafondo Vieira M, Huang SM. Botanical-drug interactions: a scientific perspective. Planta Med 2012; 78: 1400-1415
• 2 Zhou X, Chan K, Yeung JH. Herb-drug interactions with Danshen (Salvia miltiorrhiza): a review on the role of cytochrome P450 enzymes. Drug Metabol Drug Interact 2012; 27: 9-18
• 3 Zhu QN, Zhang D, Jin T, Wu Q, Liu J, Lu YF. Rutaecarpine effects on expression of hepatic phase-1, phase-2 metabolism and transporter genes as a basis of herb-drug interactions. J Ethnopharmacol 2013; 147: 215-219
• 4 Han HK. Role of transporters in drug interactions. Arch Pharm Res 2011; 34: 1865-1877
• 5 Li L, Hu H, Xu S, Zhou Q, Zeng S. Roles of UDP-glucuronosyltransferases in phytochemical metabolism of herbal medicines and the associated herb-drug interactions. Curr Drug Metab 2012; 13: 615-623
• 6 Gong QH, Yang DL, Shi JS, Ding LJ, Liu B, Li LS. Advances in neuroharmacological effects and molecular mechanisms of icariin. Chin J New Drugs Clin Remedies 2011; 30: 481-486
• 7 Kang HK, Choi YH, Kwon H, Lee SB, Kim DH, Sung CK, Park YI, Dong MS. Estrogenic/antiestrogenic activities of a Epimedium koreanum extract and its major components: in vitro and in vivo studies. Food Chem Toxicol 2012; 50: 2751-2759
• 8 Kapoor S. Icariin and its emerging role in the treatment of osteoporosis. Chin Med J (Engl) 2013; 126: 400-404
• 9 Li L, Zhou QX, Shi JS. Protective effects of icariin on neurons injured by cerebral ischemia/reperfusion. Chin Med J (Engl) 2005; 118: 1637-1643
• 10 Luo Y, Nie J, Gong QH, Lu YF, Wu Q, Shi JS. Protective effects of icariin against learning and memory deficits induced by aluminium in rats. Clin Exp Pharmacol Physiol 2007; 34: 792-795
• 11 Xu RX, Wu Q, Luo Y, Gong QH, Yu LM, Huang XN, Sun AS, Shi JS. Protective effects of icariin on cognitive deficits induced by chronic cerebral hypoperfusion in rats. Clin Exp Pharmacol Physiol 2009; 36: 810-815
• 12 Li F, Gong QH, Wu Q, Lu YF, Shi JS. Icariin isolated from Epimedium brevicornum Maxim attenuates learning and memory deficits induced by d-galactose in rats. Pharmacol Biochem Behav 2010; 96: 301-305
• 13 Nie J, Luo Y, Huang XN, Gong QH, Wu Q, Shi JS. Icariin inhibits beta-amyloid peptide segment 25–35 induced expression of beta-secretase in rat hippocampus. Eur J Pharmacol 2010; 626: 213-218
• 14 Guo J, Li F, Wu Q, Gong Q, Lu Y, Shi J. Protective effects of icariin on brain dysfunction induced by lipopolysaccharide in rats. Phytomedicine 2010; 17: 950-955
• 15 Jin F, Gong QH, Xu YS, Wang LN, Jin H, Li F, Li LS, Ma YM, Shi JS. Icariin, a phosphodiesterase-5 inhibitor, improves learning and memory in APP/PS1 transgenic mice by stimulation of NO/cGMP signalling. Int J Neuropsychopharmacol 2014; 11: 1-11
• 16 Wang M, Sun AS, Wu Q, Yu LM, Xie XL, Gong Q-H, Shi JS. Effects of icariin on the contents of liver microsomal cytochrome P450 and the activities of CYP2E1. West China J Pharmaceut Sci 2009; 24: 101-104
• 17 Li LS, Chen L, Wang AB, Lu YF, Liu J, Shi JS. Effects of icariin on liver microsomal cytochrome P450 in rats with different ages. West China J Pharmaceut Sci 2011; 27: 376-378
• 18 Li Z, Cheung FS, Zheng J, Chan T, Zhu L, Zhou F. Interaction of the bioactive flavonol, icariin, with the essential human solute carrier transporters. J Biochem Mol Toxicol 2014; 28: 91-97
• 19 Wu LX, Guo CX, Qu Q, Yu J, Chen WQ, Wang G, Fan L, Li Q, Zhang W, Zhou HH. Effects of natural products on the function of human organic anion transporting polypeptide 1B1. Xenobiotica 2012; 42: 339-348
• 20 Cao YF, He RR, Cao J, Chen JX, Huang T, Liu Y. Drug-drug interactions potential of icariin and its intestinal metabolites via inhibition of intestinal UDP-glucuronosyltransferases. Evid Based Complement Alternat Med 2012; 2012: 395912
• 21 Li LS, Liu J, Wang AB, Chen L, Lu YF, Liu J. Effects of icariin on hepatic phase II drug metabolism enzymes and transporters in rats of different age. Acta Acad Med Zunyi 2012; 35: 13-16
• 22 Rowland A, Miners JO, Mackenzie PI. The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification. Int J Biochem Cell Biol 2013; 45: 1121-1132
• 23 Klaassen CD. Learning to program the liver. Annu Rev Pharmacol Toxicol 2014; 54: 1-8
• 24 Buckley DB, Klaassen CD. Induction of mouse UDP-glucuronosyltransferase mRNA expression in liver and intestine by activators of aryl-hydrocarbon receptor, constitutive androstane receptor, pregnane X receptor, peroxisome proliferator-activated receptor alpha, and nuclear factor erythroid 2-related factor 2. Drug Metab Dispos 2009; 37: 847-856
• 25 Aleksunes LM, Klaassen CD. Coordinated regulation of hepatic phase I and II drug-metabolizing genes and transporters using AhR-, CAR-, PXR-, PPARα-, and Nrf2-null mice. Drug Metab Dispos 2012; 40: 1366-1379
• 26 Buckley DB, Klaassen CD. Tissue- and gender-specific mRNA expression of UDP-glucuronosyltransferases (UGTs) in mice. Drug Metab Dispos 2007; 35: 121-127
• 27 Zhang WP, Bai XJ, Zheng XP, Xie XL, Yuan ZY. Icariin attenuates the enhanced prothrombotic state in atherosclerotic rabbits independently of its lipid-lowering effects. Planta Med 2013; 79: 731-736
• 28 Mackenzie PI, Owens IS, Burchell B, Bock KW, Bairoch A, Bélanger A, Fournel-Gigleux S, Green M, Hum DW, Iyanagi T, Lancet D, Louisot P, Magdalou J, Chowdhury JR, Ritter JK, Schachter H, Tephly TR, Tipton KF, Nebert DW. The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 1997; 7: 255-269
• 29 Owens IS, Basu NK, Banerjee R. UDP-glucuronosyltransferases: gene structures of UGT1 and UGT2 families. Methods Enzymol 2005; 400: 1-22